[Skip to Content]
[Skip to Content Landing]
Views 204
Citations 0
Comment & Response
May 2018

Safety of Estradiol Treatment in Perimenopausal Asymptomatic Women

Author Affiliations
  • 1Gynecology Endocrinology Unit, Port-Royal Hospital, University Paris Descartes, Equipe EPOPé, Inserm, Paris, France
  • 2Gynecology Endocrinology Unit, Port-Royal Hospital, University Paris Descartes, Paris, France
JAMA Psychiatry. 2018;75(5):528-529. doi:10.1001/jamapsychiatry.2018.0615

To the Editor In their article, Gordon et al1 assessed the efficacy of transdermal estradiol and micronized progesterone in the primary prevention of depressive symptoms during menopause transition. They concluded that 12 months of transdermal estradiol associated with intermittent micronized progesterone was more effective than placebo in preventing the development of clinically significant depressive symptoms among initially euthymic perimenopausal and early postmenopausal women.

×